Darcy Lewis


Study Shows Zejula's Benefit in Treating Ovarian Cancer

June 15, 2017

Superior progression-free survival (PFS) was seen in patients with ovarian cancer who previously had a partial response (PR) to platinum-based therapy when they took Zejula (niraparib). This response was seen in patients with or without germline BRCA mutations, according to data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.

Autologous Vaccine Delays Progression Following Surgery for Ovarian Cancer

March 30, 2015

Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage 3/4 ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not, according to an open-label phase 2 trial.